Research
Hormonal
Tirzepatide significantly reduces body weight and improves lipid profiles (lowering LDL-C and triglycerides, raising HDL-C) in patients with T2DM and obesity.
Tirzepatide is a once-weekly injection that significantly reduces body weight and improves lipid profiles (lowering bad cholesterol and triglycerides, raising good cholesterol) in patients with T2DM and obesity. The benefits are dose-dependent.
StrongSupportsVERY_HIGH confidence
Tirzepatide has also been shown to significantly reduce body weight in clinical trials... Tirzepatide has been shown to improve lipid profiles in clinical studies. In humans, tirzepatide, whether used as monotherapy or add-on therapy, lowered the percentage change of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TGs) and significantly increased high-density lipoprotein cholesterol (HDL-C).
Why this rating
Based on multiple large phase 3 clinical trials (SURPASS, SURMOUNT).
Source
The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist
Yun Kyung Cho et al. · Journal of Lipid and Atherosclerosis · 2023
DOI 10.12997/jla.2023.12.3.213
narrative_reviewCited 52×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces systolic and diastolic blood pressure in patients with type 2 diabetes and obesity.Good
- Tirzepatide reduces inflammatory markers associated with cardiovascular risk, including YKL-40, ICAM-1, leptin, and GDF-15.Good
- Tirzepatide does not increase the risk of major adverse cardiovascular events (MACEs) in patients with type 2 diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →